FDA hands out two key regulatory approvals

Two big regulatory wins for developers were announced this morning. The FDA has approved Shire's Vyvanse for ADHD, giving the company a successor to Adderall. And Eli Lilly's Cymbalta won approval as a therapy for generalized anxiety disorder.

Vyvanse is amphetamine based, but only becomes effective after it enters the digestive tract. The company says that the digestive trigger mechanism should make the drug less liable for abuse by users who snort or inject pills. Cymbalta, which is already approved for depression and numbness in the limbs, is an SNRI drug, a class that includes Effexor.

- see the press release on Vyvanse
- check out this release on Cymbalta
- read the MarketWatch report on Cymbalta

Suggested Articles

The money will support work on a biologic drug cocktail that Lumen thinks can be a scalable, inexpensive fix for gastrointestinal symptoms.

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.

Scientists at the University of Toronto, in collaboration with Agios, identified 182 genes that allow cancer cells to evade the immune system.